Home / Stocks / Zota Health Care Limited
ZOTA

Zota Health Care Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,306.0

Change

-8.5 (-0.65%)

Open

₹1,319.0

Prev. Close

₹1,314.5

Day High

₹1,319.0

Day Low

₹1,298.5

Volume Analysis

Traded

29,139

Delivered

20,283

Delivery %

69.61%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (4)

  • •Low return on equity (-15.0%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (47/100)
  • •Low operating margin (0.0%)

Opportunities (2)

  • •Strong 3-year revenue growth (57.0%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,337.66 ₹1,328.33 ₹1,317.16 ₹1,307.83 ₹1,296.66 ₹1,287.33 ₹1,276.16
Fibonacci ₹1,328.33 ₹1,320.5 ₹1,315.66 ₹1,307.83 ₹1,300.0 ₹1,295.16 ₹1,287.33
Camarilla ₹1,311.64 ₹1,309.76 ₹1,307.88 ₹1,307.83 ₹1,304.12 ₹1,302.24 ₹1,300.36

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-14.09%

1 Week

+0.25%

1 Month

-0.24%

3 Months

+20.1%

6 Months

+9.51%

1 Year

-21.78%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-14.4%

Net margin -16.79% × asset turnover 0.49x × equity multiplier 1.75x

Company Overview

Sector

Healthcare

Market Cap

₹4,492 Cr

ROE

-15.0%

Book Value

₹181.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Zota Health Care Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 47/100. The strongest factor is Growth (100/100), while Cash Flow (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-15.0%); promoter holding is falling. Strong 3-year revenue growth (57.0%).

TopFund Score — Fundamentals Quality

47/100 — Weak

Data confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

92

Growth

100

Valuation

11

Cash Flow

0

Corporate Governance

43

Momentum

38

Institutional Ownership

61

Business Quality

20

Risk & Volatility

40

Liquidity

58

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 7.18 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -19.9% over last 3 years.
  • −Earnings include an other income of Rs.5.83 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

CRISIL monitoring report for QIP funds quarter ended September 30, 2026 shows no deviations.

Zota Health Care posted Q2 FY27 revenue of ₹199.33 crore; Davaindia stores reached 2,840, with EBITDA turning positive.

Published newspaper ads for Q2 and half-year FY2026 unaudited standalone and consolidated results on October 30, 2026.

Audio recording link shared for Q2 and half-year FY2026 earnings conference call held October 29, 2026.

Zota Health Care reports no deviation in ₹34,999.99 lakh QIP proceeds for quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 45 47 50 56 67 72 97 104 129 143 163 174 199
Expenses + 41 44 51 58 68 78 95 100 123 143 154 185 196
Operating Profit 4 3 -1 -1 -1 -6 2 4 6 0 9 -12 3
OPM % 10.0% 7.0% -3.0% -2.2% -1.3% -8.0% 2.5% 3.8% 4.9% -0.3% 5.0% -7.0% 1.5%
Other Income + 0 0 0 0 1 1 1 1 2 2 -3 2 5
Interest 1 1 2 3 3 2 3 3 4 5 5 6 6
Depreciation 5 5 7 8 10 11 14 15 19 22 27 28 29
Profit before tax -1 -3 -10 -12 -13 -18 -14 -13 -14 -26 -26 -44 -27
Tax % 49.0% 7.0% -27.0% 5.0% -4.0% 2.0% -10.0% 5.0% 13.0% 14.0% -45.0% 1.0% -4.0%
Net Profit + -2 -3 -7 -13 -12 -19 -13 -14 -16 -30 -14 -44 -26
EPS in Rs -1 -1 -3 -5 -4 -7 -5 -5 -5 -9 -4 -13 -7
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 16 34 35 46 49 54 96 84 92 98 68 68 55

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 25 38 50 56 85 95 106 131 139 180 292 538 679
Expenses + 21 33 43 47 77 90 105 116 132 173 298 520 679
Operating Profit 4 5 6 8 8 5 1 15 7 8 -6 19 0
OPM % 14.0% 13.0% 13.0% 15.0% 9.0% 4.8% 0.6% 11.0% 5.0% 4.2% -2.0% 3.4% 0.0%
Other Income + 0 0 0 0 2 2 2 2 2 1 2 1 6
Interest 0 1 1 1 0 0 0 0 3 5 11 17 23
Depreciation 0 1 1 2 1 2 3 4 12 20 43 82 106
Profit before tax 3 3 5 6 8 4 0 12 -5 -16 -58 -80 -123
Tax % 34.0% 33.0% 33.0% 33.0% 29.0% 29.0% -41.0% 28.0% 23.0% -11.0% -2.0% -7.0% —
Net Profit + 2 2 3 4 6 3 0 9 -6 -14 -57 -74 -114
EPS in Rs 1 1 2 2 2 1 0 4 -2 -6 -20 -21 -33
Dividend Payout % 0.0% 50.0% 38.0% 34.0% 32.0% 90.0% -1,170.0% 42.0% -44.0% -18.0% -5.0% -5.0% —
Sales growth — 52 — 13 — 11 12 23 7 29 62 84 69

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 5 3 4 4 51 44 42 64 55 64 195 659 591
Borrowings + 3 6 5 5 0 0 0 15 45 95 140 270 271
Other Liabilities + 5 10 14 17 21 20 19 35 33 43 76 167 197
Total Liabilities 20 29 35 40 90 88 85 139 158 228 439 1,131 1,094
Fixed Assets + 8 10 9 8 10 15 14 29 62 103 185 369 382
CWIP 0 0 0 0 2 0 0 0 3 5 6 15 5
Investments 0 0 0 0 16 14 10 33 8 5 54 264 168
Other Assets + 12 19 26 32 63 59 61 77 85 116 193 483 538
Total Assets 20 29 35 40 90 88 85 139 158 228 439 1,131 1,094
Equity Capital 7 10 12 14 18 25 25 25 25 26 29 35 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2011 Mar 2012 Mar 2014 Mar 2015 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + — — 3 5 -3 6 -1 13 -2 -6 -50 -82
Cash from Investing Activity + — — -1 -1 9 -4 4 -27 15 -13 -92 -330
Cash from Financing Activity + — — -2 -4 -6 -3 -2 14 -14 19 145 503
Net Cash Flow — — 0 0 -1 -1 1 1 -1 0 3 92
Free Cash Flow — — 2 4 -6 -1 -2 10 -13 -23 -96 -208
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit — — 78 81 -12 147 -134 115 2 -59 811 -380

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 66.15% → 49.38%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 33.85% 33.85% 35.55% 36.6% 36.71% 36.33% 34.52% 35.75% 34.06% 36.0% 35.96% 36.4%
Promoters 66.15% 66.15% 64.44% 62.4% 62.02% 59.72% 57.42% 55.81% 50.64% 49.38% 49.38% 49.38%
FII 0.0% 0.0% 0.01% 0.01% 0.24% 0.87% 3.82% 3.49% 8.09% 8.21% 7.92% 6.92%
DII 0.0% 0.0% 0.0% 0.99% 1.03% 3.08% 4.25% 4.95% 7.22% 6.4% 6.75% 7.3%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Zota Health Care Limited (this stock) 4,492 — 7.17 -15.0%
Sms Pharmaceuticals Ltd. 4,421 37.8 5.24 14.3%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Rpg Life Sciences Ltd 4,310 37.6 6.26 19.3%

Which Mutual Funds Hold Zota Health Care Limited?

Frequently Asked Questions about Zota Health Care Limited

Community Sentiment

What are other investors saying about Zota Health Care Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.